Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sema4 Holdings Corp. - Class A Common Stock (NQ: SMFR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.3150 (250)
Ask (Size) 0.3200 (78)
Prev. Close 0.3106
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sema4 Holdings Corp. (NASDAQ: SMFR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary... 
Via SBWire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga

Performance

More News

Read More
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
From GeneDx Holdings Corp.
Via GlobeNewswire
Sema4 Holdings's Return on Invested Capital Overview
Via Benzinga
What To Know About Goldman Sachs's Downgrade of Sema4 Holdings
Via Benzinga
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday
Via Benzinga
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
From Sema4
Via GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
NASDAQ:SMFR Investor Alert: Deadline on November 7, 2022 in Lawsuit Against Sema4 Holdings Corp.
Via SBWire
Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
SMFR FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Earnings Scheduled For November 14, 2022
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SMFR FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SEMA4 HOLDINGS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Sema4 Holdings Corp. - SMFR
From Kahn Swick & Foti, LLC
Via Business Wire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.